Group 1 - The company has raised a total of RMB 1,577,739,984.00 through a private placement of 48,004,800 shares at a price of RMB 33.33 per share, with a net amount of RMB 1,575,241,979.20 after deducting issuance costs [1][2] - The company has established a special account for the management and use of the raised funds, ensuring compliance with relevant laws and regulations [2][3] - The company has signed multiple regulatory agreements with various banks and its sponsor to ensure proper oversight of the raised funds [3] Group 2 - The company has completed the investment projects funded by the raised capital, including the "New and Relocated Plasma Collection Station Project" and "Information Technology Construction Project" [4] - A total of RMB 4.0496 million from the special account has been transferred to other fundraising accounts, and the company has initiated the closure of certain fundraising accounts [4][5] - The closure of the fundraising accounts has been communicated to the sponsor and relevant parties, and the associated regulatory agreements have been terminated [4][5]

证券代码：000403 证券简称：派林生物 公告编号：2025-034 派斯双林生物制药股份有限公司 关于部分募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、公司募集资金的基本情况 经中国证券监督管理委员会《关于核准南方双林生物制药股份有限公司向哈尔 滨同智成科技开发有限公司等发行股份购买资产并募集配套资金的批复》（证监许 可【2020】3412号），同意公司向特定对象非公开发行人民币普通股（A股）191,595,895 股股份购买相关资产，并发行股份募集配套资金不超过 16 亿元。派斯双林生物制药 股份有限公司（以下简称"公司""上市公司"）本次向特定对象非公开发行人民 币普通股（A 股）48,004,800 股，每股面值 1.00 元，每股发行认购价格为人民币 33.33 元，共计募集资金人民币 1,599,999,984.00 元。截至 2021 年 2 月 3 日，公司实际已 向特定对象非公开发行人民币普通股（A 股）48,004,800 股，募集资金总额 1,599,999,984.00 元，扣除承销费 21,730 ...

Core Viewpoint - The Chinese blood products industry is undergoing significant consolidation, with major players engaging in aggressive mergers and acquisitions to capture plasma resources, leading to the emergence of potential super giants in the sector [1][5]. Industry Landscape - The blood products industry in China is characterized by a "four-way" competitive landscape, dominated by four major groups: China National Pharmaceutical Group (Sinopharm), Haier Group, China Resources, and Hualan Biological Engineering [2][4]. - The industry has transitioned into a stock competition era since 2001, with new entrants needing to acquire existing licensed companies due to a moratorium on new licenses [2][3]. Mergers and Acquisitions - Significant acquisitions include China Resources' acquisition of Boya Biological for 4.8 billion yuan, Haier's 12.5 billion yuan acquisition of Shanghai Laishi, and Sinopharm's 4.5 billion yuan acquisition of Pilin Biological [1][2]. - The consolidation trend has led to a sharp increase in market concentration, with the top five companies' market share rising from under 50% in 2019 to over 70% by 2024 [4]. Plasma Collection and Utilization - Sinopharm's network includes 154 plasma collection stations, accounting for nearly 40% of the national total, with a collection volume of over 4,000 tons by mid-2025 [3]. - The cost structure of blood products heavily relies on raw plasma, which constitutes over 60% of total costs, making scale efficiency crucial for profitability [5][6]. Market Demand and Supply Gap - The domestic blood products market surpassed 60 billion yuan in 2023, with a demand gap of 4,000 tons, highlighting the need for leading companies to enhance their supply capabilities through technological upgrades [5][6]. - China's per capita consumption of blood products is significantly lower than that of developed countries, indicating a structural supply-demand imbalance [7][8]. Technological Advancements - Companies are shifting from a resource-driven model to a dual strategy of resource acquisition and research and development to overcome technological barriers and meet high-value product demands [9][10]. - Sinopharm and Hualan Biological are focusing on developing high-purity albumin and advanced coagulation factors, with significant investments in R&D to support these initiatives [10][11]. Future Outlook - The ongoing consolidation and technological advancements suggest that the Chinese blood products industry is on the verge of producing a super giant capable of competing globally [5][11]. - The combination of policy support, resource acquisition, and technological innovation is expected to drive the industry towards a more competitive and innovative future [10][11].

证券代码：000403 证券简称：派林生物 公告编号：2025-033 派斯双林生物制药股份有限公司 关于公司部分董监高及核心管理人员 增持公司股份计划期满暨增持结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、增持计划的基本情况：派斯双林生物制药股份有限公司（以下简称"公司"） 于2024年12月28日披露了《关于公司部分董监高及核心管理人员增持公司股份计划 的公告》（公告编号：2024-067），公司部分董监高及核心管理人员计划自2024年12 月28日起6个月内，通过二级市场集中竞价或相关法律法规允许的其他方式增持公司 股份，合计拟增持金额不低于人民币500万元。 2、增持计划实施情况：截止本公告披露日，本次增持计划实施期限已届满，增 持主体合计增持公司股份311,610股，增持金额合计人民币5,079,589.00元，已实施完 成本次增持公司股份计划。 公司于近日接到公司部分董事、监事、高级管理人员及核心管理人员的通知， 公司股票增持计划已实施完毕，现将有关情况公告如下： 中竞价或相关法律法规允许的其他方式增持公司股份，拟合计 ...

第十届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 证券代码：000403 证券简称：派林生物 公告编号：2025-032 派斯双林生物制药股份有限公司 根据公司全资子公司哈尔滨派斯菲科生物制药有限公司实际经营管理需要，董事 会同意对《哈尔滨派斯菲科生物制药有限公司章程》进行修订，经营范围增加道路货 物运输（不含危险货物），其他条款内容保持不变。 表决结果：13票同意、0票反对、0票弃权。本议案表决结果为通过。 三、备查文件 第十届董事会第十六次会议决议。 特此公告。 派斯双林生物制药股份有限公司 董 事 会 派斯双林生物制药股份有限公司（以下简称"公司"）第十届董事会第十六次会议 于 2025 年 6 月 27 日以通讯方式召开，会议由公司董事长李昊先生召集并主持。会议 应出席董事 13 人，实际出席董事 13 人，会议程序符合《公司法》和《公司章程》的 有关规定。 二、董事会会议审议情况 与会董事经过认真讨论，审议了以下议案： 1、《关于修改子公司<哈尔滨派斯菲科生物制药有限公司章程>的议案》 二〇二 ...

Core Insights - The Chinese pharmaceutical industry is undergoing a new round of deep integration driven by policy guidance and market demand [1][2] - China National Pharmaceutical Group (Sinopharm) has announced acquisitions of two listed companies, Plasmed Biopharma and Shandong Pharmaceutical Glass, exemplifying recent M&A activity in the sector [1][2] Industry Trends - State-owned enterprises are becoming the main players in the M&A market, significantly altering the competitive landscape with their strong financial capabilities and resource integration skills [2][3] - Major industry players like Sinopharm, China Resources Pharmaceutical Group, and China General Technology Group are building competitive advantages across the entire supply chain through horizontal and vertical integration [2][3] Company Strategies - Sinopharm is focusing on strengthening its acquisition and integration strategies, aiming to enhance its market position in the health sector [3][4] - The acquisition of Plasmed Biopharma and Shandong Pharmaceutical Glass will allow Sinopharm to consolidate its supply chain, ensuring the safety and stability of the biopharmaceutical supply chain [4][6] Market Dynamics - The blood products sector is particularly strategic due to the limited number of licenses available since 2001, making existing licenses and plasma stations highly valuable [4][5] - Following the acquisition, Sinopharm's combined plasma collection volume from its subsidiaries is expected to exceed 4,181 tons, accounting for 31.2% of the national total [4][5] Financial Performance - Shandong Pharmaceutical Glass, as a leading player in the pharmaceutical glass sector, reported a revenue of 5.125 billion and a net profit of 943 million in 2024, marking 12 consecutive years of growth [5][6] Future Outlook - The M&A trend in the pharmaceutical industry is expected to evolve towards integrated supply chain acquisitions, cross-border expansions, and innovative ecosystem constructions [7]

一、 股权分置改革方案的相关情况 根据国务院《关于推进资本市场改革开放和稳定发展的若干意见》、中国证 监会、国资委、财政部、中国人民银行和商务部联合发布的《关于上市公司股权 分置改革的指导意见》以及中国证监会《上市公司股权分置改革管理办法》等文 件的精神及要求，派林生物股权分置改革方案经 2007 年 12 月 24 日现场召开的 三九宜工生化股份有限公司（即派斯双林生物制药股份有限公司）2007 年第二 次临时股东大会暨相关股东会议表决通过。派林生物本次股权分置改革以 2013 年 1 月 8 日为股权分置改革方案实施的股权登记日，具体方案为：以公司资本公 积中的 6,089.4108 万元向本次股权分置改革股权登记日登记在册的流通股股东 定向转增股本，每 10 股流通股股东获得转增 6 股，相当于流通股股东每 10 股获 非流通股股东付出 2.426 股。非流通股股东由此获得所持非流通股份的流通权。 西南证券股份有限公司关于派斯双林生物制药股份 有限公司解除部分股份限售的核查意见 深圳证券交易所： 作为派斯双林生物制药股份有限公司（以下简称"派林生物"、"上市公 司"、"公司"）股权分置改革的保荐机构，西 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-031 派斯双林生物制药股份有限公司 解除股份限售的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次解除限售股份股东数量为3名，解除限售股份的数量为991,607股，占公 司总股本比例0.1043%； 2、本次限售股份可上市流通日期：2025年6月25日。 一、股权分置改革方案概述 1、股权分置改革对价方案概述 以公司资本公积中的6,089.4108万元向股权分置改革股权登记日登记在册的流 通股股东定向转增股本，每10股流通股股东获得转增6股，相当于流通股股东每10股 获非流通股股东付出2.426股。 2、通过股权分置改革方案的股东大会日期、届次 派斯双林生物制药股份有限公司股权分置改革方案经2007年12月24日召开的 三九宜工生化股份有限公司（即派斯双林生物制药股份有限公司）2007年第二次临 时股东大会暨相关股东会议审议通过。 2012年12月17日，公司召开2012年第二次临时股东大会审议通过了《关于公司 股权分置改革特别承诺事项优化履行暨关联交易方案的议 ...

Core Viewpoint - The blood products industry is experiencing significant consolidation, highlighted by China National Pharmaceutical Group's acquisition of a 21.03% stake in Palin Bio for 4.6 billion yuan, which is a high premium acquisition that will reshape the industry landscape [1][5]. Company Summary - China National Pharmaceutical Group's acquisition will increase its control over the blood products market, consolidating its position as the leading player with a total of 154 plasma stations across its subsidiaries, including Tian Tan Biological and Wei Guang Biological [6][9]. - Palin Bio has undergone multiple ownership changes, with its history marked by internal conflicts that have hindered its growth. The company has changed hands six times, with the latest acquisition by China National Pharmaceutical Group marking a potential end to its tumultuous ownership history [3][4]. Industry Summary - The blood products industry is characterized by a high degree of concentration, with major players like Tian Tan Biological, Shanghai Laishi, and Palin Bio dominating the market. The industry is moving towards an oligopolistic structure, with the number of companies decreasing significantly over the years [8][11]. - The global blood products market is projected to exceed $50 billion in 2024 and reach over $90 billion by 2030, indicating substantial growth potential driven by increasing demand for blood products due to aging populations and the need for critical medical supplies [8][10]. - China's blood products market is expected to grow significantly, with projections of reaching 60 billion yuan in 2024 and 95 billion yuan by 2030. The industry faces challenges such as limited raw material supply and strict regulations on blood plasma collection [11][12].

Core Viewpoint - The acquisition of a 21.03% stake in Pailin Biopharmaceuticals by China National Pharmaceutical Group is a strategic move to reshape the competitive landscape in the blood products industry, potentially enhancing market share and resource integration [2][5][13]. Group 1: Acquisition Details - Pailin Biopharmaceuticals announced a framework agreement for the acquisition, with a transaction value of approximately 4.6 billion yuan, calculated based on the principal of 3.844 billion yuan and an annualized interest of 9% [2]. - If the acquisition is completed, the actual controller of Pailin Biopharmaceuticals will change from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group [2][5]. Group 2: Industry Context - The blood products industry is experiencing a wave of mergers and acquisitions, with major players like China National Pharmaceutical Group and China Biotech aiming to increase market concentration [5][14]. - The industry is characterized by high barriers to entry, scarcity of plasma collection resources, and strict regulatory oversight, making the acquisition of existing companies a strategic necessity for growth [13][14]. Group 3: Historical Control Changes - Pailin Biopharmaceuticals has undergone five changes in control since its listing, reflecting the intense capital competition in the blood products sector over the past two decades [6][7]. - The company was previously embroiled in ownership disputes, which affected its strategic direction until a stable control was established in 2019 [6][7]. Group 4: Financial Performance - Pailin Biopharmaceuticals reported a revenue of 10.5 billion yuan in 2020, with a year-on-year growth of 14.67%, and net profit of 1.86 billion yuan, marking a 15.90% increase [9]. - The company achieved a revenue of 24.05 billion yuan in 2022, with a net profit of 5.87 billion yuan, benefiting from continuous investment in product development and market expansion [9][10]. - However, in 2023, the company faced a slight revenue decline of 3.18% to 23.29 billion yuan, although net profit increased to 6.12 billion yuan [9][10]. Group 5: Future Outlook - In 2024, Pailin Biopharmaceuticals is projected to achieve a revenue of 26.55 billion yuan, a 14% increase, driven by rising demand for blood products and increased plasma collection [10]. - The company anticipates challenges in 2025, with expected declines in revenue and net profit due to production capacity expansion and supply issues [11][12].